The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels

Cunningham, K., Clapp. L.H., Mathie, A. and Veale, E.L. 2021. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels. Frontiers in Pharmacology. 12 705421. https://doi.org/10.3389/fphar.2021.705421

TitleThe Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
TypeJournal article
AuthorsCunningham, K., Clapp. L.H., Mathie, A. and Veale, E.L.
Abstract

Pulmonary arterial hypertension (PAH) is an aggressive vascular remodeling disease that carries a high morbidity and mortality rate. Treprostinil (Remodulin) is a stable prostacyclin analogue with potent vasodilatory and anti-proliferative activity, approved by the FDA and WHO as a treatment for PAH. A limitation of this therapy is the severe subcutaneous site pain and other forms of pain experienced by some patients, which can lead to significant non-compliance. TWIK-related potassium channels (TREK-1 and TREK-2) are highly expressed in sensory neurons, where they play a role in regulating sensory neuron excitability. Downregulation, inhibition or mutation of these channels leads to enhanced pain sensitivity. Using whole-cell patch-clamp electrophysiological recordings, we show, for the first time, that treprostinil is a potent antagonist of human TREK-1 and TREK-2 channels but not of TASK-1 channels. An increase in TASK-1 channel current was observed with prolonged incubation, consistent with its therapeutic role in PAH. To investigate treprostinil-induced inhibition of TREK, site-directed mutagenesis of a number of amino acids, identified as important for the action of other regulatory compounds, was carried out. We found that a gain of function mutation of TREK-1 (Y284A) attenuated treprostinil inhibition, while a selective activator of TREK channels, BL-1249, overcame the inhibitory effect of treprostinil. Our data suggests that subcutaneous site pain experienced during treprostinil therapy may result from inhibition of TREK channels near the injection site and that pre-activation of these channels prior to treatment has the potential to alleviate this nociceptive activity.

Article number705421
JournalFrontiers in Pharmacology
Journal citation12
ISSN1663-9812
Year2021
PublisherFrontiers
Publisher's version
License
CC BY 4.0
File Access Level
Open (open metadata and files)
Digital Object Identifier (DOI)https://doi.org/10.3389/fphar.2021.705421
Web address (URL)http://dx.doi.org/10.3389/fphar.2021.705421
Publication dates
Published29 Jun 2021

Related outputs

Propofol rescues voltage-dependent gating of HCN1 channel epilepsy mutants
Elizabeth D. Kim, Xiaoan Wu, Sangyun Lee, Gareth R. Tibbs, Kevin P. Cunningham, Eleonora Di Zanni, Marta E. Perez, Peter A. Goldstein, Alessio Accardi, H. Peter Larsson and Crina M. Nimigean 2024. Propofol rescues voltage-dependent gating of HCN1 channel epilepsy mutants. Nature. 632, pp. 451-459. https://doi.org/10.1038/s41586-024-07743-z

Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism
Wu, X, Cunningham, K.P., Bruening-Wright, A, Pandey, S and Larsson, H. P. 2024. Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism. International Journal of Molecular Sciences. 25 (8) 4309. https://doi.org/10.3390/ijms25084309

Preprint: Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism
Xiaoan Wu, Kevin P. Cunningham, Andrew Bruening-Wright, Shilpi Pandey and H. Peter Larsson 2024. Preprint: Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism. Preprints.org. https://doi.org/10.20944/preprints202403.0499.v1

Preprint: Binding of PUFA stabilizes a conductive state of the selectivity filter in IKs channels
Alessia Golluscio, Jodene Eldstrom, Jessica J. Jowais, Marta E. Perez-Rodriguez, Kevin P. Cunningham, Alicia de la Cruz, Xiaoan Wu, David Fedida and H. Peter Larsson 2024. Preprint: Binding of PUFA stabilizes a conductive state of the selectivity filter in IKs channels. arXiv. https://doi.org/10.1101/2024.01.11.575247

Similar voltage-sensor movement in spHCN channels can cause closing, opening, or inactivation
Xiaoan Wu, Kevin P. Cunningham, Rosamary Ramentol, Marta E. Perez and H. Peter Larsson 2023. Similar voltage-sensor movement in spHCN channels can cause closing, opening, or inactivation. Journal of General Physiology. 155 (5) e202213170. https://doi.org/10.1085/jgp.202213170

Artemisinin inhibits neutrophil and macrophage chemotaxis, cytokine production and NET release
Morad, H.O.J., Luqman, S., Garcia Pinto, L., Cunningham, K., Vilar, B., Clayton, G., Shankar-Hari, M. and McNaughton, P.A. 2022. Artemisinin inhibits neutrophil and macrophage chemotaxis, cytokine production and NET release. Scientific Reports. 2022 (12) 11078. https://doi.org/10.1038/s41598-022-15214-6

Preprint: Artemisinin inhibits innate immune cell chemotaxis, cytokine production and NET release
Morad, H., Luqman, S., Pinto, L., Cunningham, K.P., Vilar, B., Clayton, G., Shankar-Hari, M. and McNaughton, P.A. 2022. Preprint: Artemisinin inhibits innate immune cell chemotaxis, cytokine production and NET release. https://doi.org/10.21203/rs.3.rs-1335980/v1

Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond.
Mathie, A., Veale, E.L., Cunningham, K.P., Holden, R.G. and Wright, P.D. 2021. Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond. Annual Review of Pharmacology and Toxicology. 61, pp. 401-420. https://doi.org/10.1146/annurev-pharmtox-030920-111536

Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channels
Kevin P. Cunningham, D. Euan MacIntyre, Alistair Mathie and Emma L. Veale 2020. Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channels. Acta Physiologica. 228 (2) e13361. https://doi.org/10.1111/apha.13361

Characterization and regulation of wild‐type and mutant TASK‐1 two pore domain potassium channels indicated in pulmonary arterial hypertension
Cunningham, K.P., Holden, R.G., Escribano‐Subias, P.M., Cogolludo, A., Veale, E.L. and Mathie, A. 2019. Characterization and regulation of wild‐type and mutant TASK‐1 two pore domain potassium channels indicated in pulmonary arterial hypertension. Journal of Physiology. 597 (4), pp. 1087-1101. https://doi.org/10.1113/jp277275

Permalink - https://westminsterresearch.westminster.ac.uk/item/w3yz0/the-prostacyclin-analogue-treprostinil-used-in-the-treatment-of-pulmonary-arterial-hypertension-is-a-potent-antagonist-of-trek-1-and-trek-2-potassium-channels


Share this

Usage statistics

46 total views
17 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.